<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810380</url>
  </required_header>
  <id_info>
    <org_study_id>14644A</org_study_id>
    <secondary_id>2012-002252-17</secondary_id>
    <nct_id>NCT01810380</nct_id>
  </id_info>
  <brief_title>Brexpiprazole in Patients With Acute Schizophrenia</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Poland: National Institute of Medicines</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Serbia: Medicines and Medical Devices Agency</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of brexpiprazole for the treatment of adults
      experiencing an acute episode of schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in efficacy using PANSS</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive and Negative Syndrome Scale (PANSS) total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical global impression</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Global Impression - Severity of Illness (CGI-S) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of clinical global impression</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Global Impression - Global Improvement (CGI-I) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in psychotic symptoms</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>PANSS Positive Subscale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in psychotic symptoms</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>PANSS Negative Subscale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in psychotic symptoms</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>PANSS Excited Component score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in psychotic symptoms</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>PANSS Marder Factor scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on pre-specified reduction in PANSS total score or CGI-I score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in personal and social performance</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Personal and Social Performance Scale (PSP) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 6 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP) for patients who do not enter the follow-up study 14644B</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of suicidality</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Columbia-Suicide Severity Rating Scale (C-SSRS) score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">465</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine extended release</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily as tablets and capsules, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Up to 4 mg/day, once daily, tablets, orally</description>
    <arm_group_label>Brexpiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine extended release</intervention_name>
    <description>Up to 800 mg/day, once daily, encapsulated tablets, orally</description>
    <arm_group_label>Quetiapine extended release</arm_group_label>
    <other_name>Seroquel XL®/XR®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has schizophrenia, diagnosed according to DSM-IV-TR™ and confirmed by the
             Mini International Neuropsychiatric Interview (MINI).

          -  The patient has an acute exacerbation of psychotic symptoms and marked deterioration
             of usual function.

          -  The patient is willing to be hospitalised from the Screening Visit through Week 6.

          -  The patient will benefit from hospitalisation or continued hospitalisation for
             treatment of a current acute relapse of schizophrenia at study entry.

          -  The patient has a history of relapse and/or exacerbation of symptoms when not
             receiving antipsychotic treatment, excluding the current episode.

          -  The patient agrees to protocol-defined use of effective contraception.

        Exclusion Criteria:

          -  The patient has a current Axis I diagnosis (DSM-IV-TR™ criteria) other than
             schizophrenia established as primary diagnosis.

          -  The patient suffers from a current Axis II diagnosis (DSM-IV-TR™ criteria).

          -  The patient suffers from mental retardation, organic mental disorders, or mental
             disorders due to a general medical condition (DSM-IV-TR™ criteria).

          -  The patient, in the opinion of the investigator or according to Columbia Suicide
             Severity Rating Scale (C-SSRS), is at significant risk of suicide.

          -  The patient has clinically significant tardive dyskinesia or severe akathisia at
             enrolment.

          -  The patient has a history of neuroleptic malignant syndrome.

          -  The patient has any relevant medical history or current presence of systemic disease.

          -  The patient has, at the Screening Visit an abnormal ECG or other abnormal ECG tests
             that are, in the investigator's opinion, clinically significant.

          -  The patient has a history of cancer, other than basal cell or Stage 1 squamous cell
             carcinoma of the skin, that has not been in remission for &gt;5 years prior to the first
             dose of brexpiprazole.

          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol
             or is unsuitable for any reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>US009</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quetiapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
